Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 多克隆抗體
  4. IRF4 Antibody

IRF4 Antibody

  • 中文名稱：
    IRF4兔多克隆抗體
  • 貨號(hào)：
    CSB-PA668482
  • 規(guī)格：
    ￥1100
  • 圖片：
    • Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Jurkat cells, Primary antibody: CSB-PA668482(IRF4 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes
  • 其他：

產(chǎn)品詳情

  • Uniprot No.：
  • 基因名：
  • 別名：
    Interferon regulatory factor 4 antibody; IRF 4 antibody; IRF-4 antibody; Irf4 antibody; IRF4_HUMAN antibody; LSIRF antibody; Lymphocyte specific interferon regulatory factor antibody; Lymphocyte specific IRF antibody; Lymphocyte-specific interferon regulatory factor antibody; Multiple myeloma oncogene 1 antibody; MUM 1 antibody; MUM1 antibody; NF EM5 antibody; NF-EM5 antibody; NFEM5 antibody; PU.1 interaction partner antibody; Sfpi1/PU.1 interaction partner antibody; Transcriptional activator PIP antibody
  • 宿主：
    Rabbit
  • 反應(yīng)種屬：
    Human,Mouse
  • 免疫原：
    Synthetic peptide of Human IRF4
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 抗體亞型：
    IgG
  • 純化方式：
    Antigen affinity purification
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用范圍：
    ELISA,WB
  • 推薦稀釋比：
    Application Recommended Dilution
    ELISA 1:1000-1:2000
    WB 1:200-1:1000
  • Protocols：
  • 儲(chǔ)存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    Transcriptional activator. Binds to the interferon-stimulated response element (ISRE) of the MHC class I promoter. Binds the immunoglobulin lambda light chain enhancer, together with PU.1. Probably plays a role in ISRE-targeted signal transduction mechanisms specific to lymphoid cells. Involved in CD8(+) dendritic cell differentiation by forming a complex with the BATF-JUNB heterodimer in immune cells, leading to recognition of AICE sequence (5'-TGAnTCA/GAAA-3'), an immune-specific regulatory element, followed by cooperative binding of BATF and IRF4 and activation of genes.
  • 基因功能參考文獻(xiàn)：
    1. In Pakistani population, the frequency of GCB type DLBCL [diffuse large B cell lymphoma ]expressing CD10 and BCL6 is 37.5%, and non- GCB type DLBCL [diffuse large B cell lymphoma ] expressing MUM1 is 62.5%. PMID: 29056123
    2. Study confirmed a significant role for IRF4 rs12203592 and SLC45A2 rs16891982 in the risk of cutaneous squamous cell carcinoma development in organ transplant recipients. PMID: 27566401
    3. IRF4 is overexpressed in human non-small cell lung cancer and activates the Notch signaling pathway. PMID: 28849037
    4. IRF4 signaling is essential for activin A induced regulatory T cells that restrain asthmatic responses. PMID: 28320933
    5. The data indicate that USP4 interacts with and deubiquitinates IRF4, and also stabilizes IRF4 protein and promotes IRF4 function to facilitate IL-4 expression in Th2 cells, which may be related to the pathological process of rheumatic heart disease. PMID: 28791349
    6. IRF4 is an independent prognostic factor for general MM patients. PMID: 27223072
    7. Data show that the host transcript of miR-223, linc-223, as a novel functional long non-coding RNA (lncRNA) and induces interferon regulatory factor 4 (IRF4) expression in acute myeloid leukemia. PMID: 27517498
    8. Evidence for an essential role of Notch signaling in the development of chronic lymphocytic leukemia (CLL) and establish IRF4 as a critical regulator of Notch signaling during CLL development. PMID: 27232759
    9. These results show that significantly increased levels of FOXO3, IRF4, and xIAP mRNA in Chinese HIV-1-infected patients. PMID: 27841661
    10. Mechanistically, we found that BETi-mediated inhibition of cMYC correlates with the upregulation of miR-125b-5p and the downregulation of the cMYC/miR-125b-5p target gene IRF4, a transcriptional repressor of MICA. PMID: 27903272
    11. BCL7A, BRWD3, and AUTS2 demonstrate significantly higher mutation frequencies among AA cases. These genes are all involved in translocations in B-cell malignancies. Moreover, we detected a significant difference in mutation frequency of TP53 and IRF4 with frequencies higher among CA cases. Our study provides rationale for interrogating diverse tumor cohorts to best understand tumor genomics across populations. PMID: 29166413
    12. IRF4 protects arteries against neointima formation by promoting the expression of KLF4 by directly binding to its promoter. PMID: 28851732
    13. We propose that the Irf4 locus functions as the "reader" of TCR signal strength, and in turn, concentration-dependent activity of Irf4 "writes" T helper fate choice. PMID: 28930660
    14. PU.1-induced apoptosis in myeloma cells is associated with IRF4 downregulation and subsequent IRF7 upregulation. PMID: 28368411
    15. GM-CSF can mediate inflammation and pain by regulating IRF4-induced CCL17 production PMID: 27525438
    16. expression of CARMA1 mRNA is likely associated with the expression of MUM1 and shows male predominance in diffuse large B cell lymphoma. PMID: 21569705
    17. Data show that BCL-6 (64%) and MUM1 (45%) were expressed in patients with primary mediastinal large B-cell lymphoma. PMID: 21623692
    18. The study demonstrated differential MUM-1 expression between PEComas and other true melanocytic tumors PMID: 21903680
    19. Mum-1 was positive in all but one case (96.7%) of systemic anaplastic large-cell lymphoma by tissue microarray immunohistochem analysis. PMID: 22158496
    20. These results show that MUM1 is a strong and robust predictive immunohistochemical marker in patients with follicular lymphoma PMID: 25149549
    21. MUM1 expression is reliable in the prognosis of diffuse large B-cell lymphoma. PMID: 26414904
    22. MUM-1 could be a useful marker for the differential diagnosis of angioimmunoblastic T cell lymphoma (AITL) with Hodgkin/Reed-Sternberg like cells and classical Hodgkins lymphoma. PMID: 26617862
    23. identify PDL1 and MUM1 as prognostic biomarkers for high-risk disease in primary mediastinal large B-cell lymphoma PMID: 27419920
    24. IRF4 had independent prognostic significance in node-negative breast cancer PMID: 28251349
    25. CPEB4 and IRF4 expression in peripheral mononuclear cells are potential prognostic factors for advanced lung cancer PMID: 27113098
    26. IRF4/MUM1+ Burkitt lymphoma (BL) showed significantly worse prognosis, particularly in adult cases, compared with IRF4/MUM1- BL. PMID: 28079574
    27. This study identified a novel shared locus, IRF4, for the risk of systemic sclerosis and rheumatoid arthritis, and highlighted the usefulness of a cross-disease GWAS meta-analysis strategy in the identification of common risk loci PMID: 27111665
    28. High IRF4 expression is associated with lymphoma in Waldeyer ring. PMID: 27616053
    29. These findings suggest for the first time that IRF4 rs12203592 plays a role in the modulation of melanoma outcome and confirms its contribution to the localization of the primary tumour. PMID: 28103633
    30. results definitively show that LMP1 promotes IRF4 tyrosine phosphorylation and markedly stimulates its transcriptional activity through recruiting Src via P85 PMID: 27819673
    31. IRF4 and CRBN polymorphisms affect risk and response to treatment in multiple myeloma PMID: 28083618
    32. This meta-analysis indicates that the IL-6 gene -174G/C and interferon regulatory factor 4 polymorphisms may be associated with an increased skin cancer risk. PMID: 26928068
    33. Study demonstrate that IRF4 acts as an inhibitor of epithelial cell proliferation and mediates the expression of TIPE2, a negative regulator of TLR signaling, to control cell growth. PMID: 26781452
    34. The anti-PEL effects of IMiDs involved cereblon-dependent suppression of IRF4 and rapid degradation of IKZF1 PMID: 26119939
    35. IRF4 single nucleotide polymorphism is predictive factor of melanoma subtypes. PMID: 26907189
    36. Role of IRF4 rs12203592 in pathway-specific risk for melanoma development. Hypothesize that IRF4 rs12203592 could underlie in part the bimodal age distribution reported for melanoma and linked to the divergent pathways PMID: 26857527
    37. These results indicate that the KDM3A-KLF2-IRF4 pathway plays an essential role in multiple myeloma cell survival and homing to the bone marrow, and therefore represents a therapeutic target. PMID: 26728187
    38. FOXO1 and PR are required for the regulation of IRF4, a novel transcriptional regulator of decidualization in human endometrial stromal cells. PMID: 25584414
    39. inhibition of IRF4 translated into downregulation of c-Myc, caspase-10 and cFlip, relevant IRF4-downstream effectors PMID: 25987254
    40. Overall, our data strongly suggest that IRF4, MC1R and TYR genes likely have pleiotropic effects, a combination of pigmentation and oncogenic functions, resulting in an increased risk of actinic keratosis. PMID: 25724930
    41. collagen I induces TNF- alpha production, which is crucial for the activation and function of DCs, through down-regulation of IRF4, and implicates the importance in development of anti- TNF-alpha therapeutics for several inflammatory diseases. PMID: 25740143
    42. Allele-specific transcriptional regulation of IRF4 in melanocytes is mediated by chromatin looping of the intronic rs12203592 enhancer to the IRF4 promoter PMID: 25631878
    43. IRF4 is deregulated in B cells from common variable immunodeficiency patients, contributing to the observed aberrant expression of activation-induced deaminase in these patients. PMID: 26276871
    44. NOD2 downregulates colonic inflammation by IRF4-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6. PMID: 24670424
    45. The data are consistent with the rs4487645-CDCA7L loci being responsible for the chromosome 7p11.2 association with multiple myeloma risk, probably exerting its effects through an extended pathway involving IRF4 and MYC. PMID: 25480495
    46. IRF4 gene mutation is influencing facial pigmented spots. PMID: 25705849
    47. Twenty-two cases of nodular lymphocyte predominant Hodgkin lymphoma were studied for the immunohistochemical expression of Pax-5, Oct-2, BOB.1, Bcl-6 protein and MUM1/IRF-4. Results support the usefulness of this set of transcription factors to distinguish nodular lymphocyte predominant Hodgkin lymphoma from classical Hodgkin lymphoma. PMID: 21424034
    48. MUM-1/IRF4 expression is significantly higher in high-grade follicular lymphoma, indicating that these cases have a high proliferative activity, more aggressive behavior and poorer prognosis. PMID: 22169641
    49. the unique roles of IRF4 in different hematological malignancies PMID: 25207815
    50. These findings suggest that the IRF4 gene polymorphism is not associated with SLE in a Chinese Han population; further studies are needed to establish the role of IRF4 in SLE with a larger sample size. PMID: 24292686

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Multiple myeloma (MM)
  • 亞細(xì)胞定位：
    Nucleus.
  • 蛋白家族：
    IRF family
  • 組織特異性：
    Lymphoid cells.
  • 數(shù)據(jù)庫(kù)鏈接：

    HGNC: 6119

    OMIM: 254500

    KEGG: hsa:3662

    STRING: 9606.ENSP00000370343

    UniGene: Hs.401013